Phase 2 Gastric Cancer Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Gastric CancerSolid Tumors
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Breast CancerEsophageal CancerGastric Cancer+1 more
Jazz Pharmaceuticals200 enrolled21 locationsNCT06695845
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 1Phase 2
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521
Recruiting
Phase 1Phase 2
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Gastric CancerHepatocellular CarcinomaNon-small Cell Lung Cancer+3 more
Shanghai Public Health Clinical Center40 enrolled1 locationNCT03093688
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 2
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Breast CancerGastric CancerSarcoma+2 more
University of California, Irvine51 enrolled1 locationNCT06580002
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
ModeX Therapeutics, An OPKO Health Company115 enrolled6 locationsNCT06239194
Recruiting
Phase 1Phase 2
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
Chongqing Precision Biotech Co., Ltd60 enrolled3 locationsNCT06006390